Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine in Asian Adults with ADHD
NCT00962104Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2009
- Primary completion
- Feb 2011
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) comparing Atomoxetine with Placebo (2 arms). Primary endpoint: Conners' Adult Attention-Deficit/Hyperactivity Disorder Rating Scale-Investigator Rated: Screening Version 18-Item Total Symptom Score at 10 weeks. Started Aug 2009; status: completed.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00962104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00962104.